NMTC — Neuroone Medical Technologies Income Statement
0.000.00%
Last trade - 00:00
- $25.57m
- $23.95m
- $3.45m
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 1.93 | 0.243 | 2.12 | 3.45 |
Cost of Revenue | |||||
Gross Profit | — | — | -0.033 | 1.88 | 1.95 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 6.37 | 8.85 | 10.5 | 12.2 | 15.4 |
Operating Profit | -6.37 | -6.92 | -10.2 | -10 | -12 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.78 | -13.6 | -9.95 | -10 | -11.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.78 | -13.6 | -9.95 | -10 | -11.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.78 | -13.6 | -9.95 | -10 | -11.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.78 | -13.6 | -9.95 | -10 | -11.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.58 | -2.15 | -0.93 | -0.625 | -0.654 |